AKT1 and Familial prostate cancer: In support of an oncogenic role in prostate cancer and therapeutic resistance, conditional activation of AKT in either the LNCaP human prostate cancer cells or a transgenic mouse results in increased cell proliferation and inhibits cell death to promote tumor growth and castration-resistance in vivo [132].